
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Y mAbs Therapeutics (YMAB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: YMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $8.6
1 Year Target Price $8.6
7 | Strong Buy |
1 | Buy |
0 | Hold |
1 | Sell |
1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.91% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 387.14M USD | Price to earnings Ratio - | 1Y Target Price 8.6 |
Price to earnings Ratio - | 1Y Target Price 8.6 | ||
Volume (30-day avg) 10 | Beta 0.56 | 52 Weeks Range 3.55 - 16.11 | Updated Date 08/16/2025 |
52 Weeks Range 3.55 - 16.11 | Updated Date 08/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.26 | Actual -0.07 |
Profitability
Profit Margin -26.03% | Operating Margin (TTM) -28.7% |
Management Effectiveness
Return on Assets (TTM) -8.67% | Return on Equity (TTM) -24.31% |
Valuation
Trailing PE - | Forward PE 119.05 | Enterprise Value 327966338 | Price to Sales(TTM) 4.53 |
Enterprise Value 327966338 | Price to Sales(TTM) 4.53 | ||
Enterprise Value to Revenue 3.84 | Enterprise Value to EBITDA -0.43 | Shares Outstanding 45438400 | Shares Floating 25152892 |
Shares Outstanding 45438400 | Shares Floating 25152892 | ||
Percent Insiders 11.97 | Percent Institutions 69.64 |
Upturn AI SWOT
Y mAbs Therapeutics
Company Overview
History and Background
Y-mAbs Therapeutics, Inc. is a biopharmaceutical company founded in 2015. It focuses on developing and commercializing novel antibody-based therapeutic products for the treatment of cancer, particularly in pediatric populations. Initially focused on neuroblastoma, Y-mAbs has expanded to other cancer types. The company is built upon technology licensed from Memorial Sloan Kettering Cancer Center.
Core Business Areas
- Oncology Therapeutics Development: Focuses on the research, development, and commercialization of antibody-based therapies for various cancers.
- Pediatric Cancer Focus: Specializes in developing treatments for pediatric cancers with high unmet medical needs.
Leadership and Structure
Y-mAbs is led by a management team with experience in oncology and biopharmaceutical development. The organizational structure includes departments for research and development, clinical operations, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- DANYELZA (naxitamab-gqgk): A GD2-binding monoclonal antibody approved for the treatment of high-risk neuroblastoma in pediatric and adult patients who have demonstrated a partial response, minor response, or stable disease to prior first-line therapy. Market share data is difficult to ascertain precisely but Danyelza is a key player in the neuroblastoma treatment landscape. Competitors include standard chemotherapy regimens and other investigational therapies targeting neuroblastoma.
- OMBLASTYS (omezatamab): An investigational drug product for the treatment of DIPG that is in phase III clinical trials. As an investigational therapy it has no market share as of October 26, 2024. Competitors would include radiation therapy and other experimental DIPG therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The oncology market is a significant segment, driven by increasing cancer incidence and advances in targeted therapies and immunotherapies.
Positioning
Y-mAbs is positioned as a specialized oncology company focused on pediatric cancers. Its competitive advantage lies in its proprietary antibody technologies and its focus on addressing unmet needs in rare pediatric cancers.
Total Addressable Market (TAM)
The total addressable market (TAM) for neuroblastoma and other pediatric cancers is substantial, with significant unmet needs. The global neuroblastoma market is estimated to be in the hundreds of millions of dollars and growing. Y-mAbs is positioned to capture a significant share of this market with its approved and investigational therapies.
Upturn SWOT Analysis
Strengths
- FDA-approved product (DANYELZA)
- Proprietary antibody technologies
- Focus on underserved pediatric cancer market
- Experienced management team
- Strong relationships with leading cancer centers
Weaknesses
- Dependence on a limited number of products
- Commercialization challenges for rare diseases
- High cash burn rate
- Regulatory hurdles for new drug approvals
- Reliance on external manufacturing partners
Opportunities
- Expansion into new cancer indications
- Partnerships and collaborations with other pharmaceutical companies
- Potential for accelerated regulatory pathways for pediatric cancer therapies
- Geographic expansion into new markets
- Development of next-generation antibody therapies
Threats
- Competition from established pharmaceutical companies
- Patent expirations and generic entry
- Clinical trial failures
- Regulatory setbacks
- Economic downturns and healthcare spending constraints
Competitors and Market Share
Key Competitors
- BMRN
- NKTR
- MRTX
Competitive Landscape
Y-mAbs faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for cancer. Its advantages include its focus on pediatric cancers and its proprietary antibody technologies. Disadvantages include its limited product portfolio and commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Y-mAbs' historical growth has been driven by the approval and commercialization of DANYELZA. Revenue growth has been variable and impacted by factors such as market access and reimbursement.
Future Projections: Future growth projections depend on the success of its pipeline candidates and the expansion of DANYELZA's market reach. Analyst estimates vary widely and are subject to change. Refer to analyst reports for specific projections.
Recent Initiatives: Recent strategic initiatives include advancing the clinical development of its pipeline candidates, expanding its commercial infrastructure, and exploring partnerships and collaborations.
Summary
Y-mAbs is a biopharmaceutical company focused on pediatric oncology, primarily neuroblastoma, where it has an approved product. While it has a focused pipeline and some successes, it operates at a loss and needs additional therapy successes. Cash burn is a constant concern, so investors should carefully monitor progress and financial results. Success of Omblastys could alter the outlook considerably.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Y-mAbs Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Y mAbs Therapeutics
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2018-09-21 | CEO, President & Director Mr. Michael Rossi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.ymabs.com |
Full time employees 104 | Website https://www.ymabs.com |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.